Skip to content

Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography

Comparison of Diagnostic Performance of Urothelial Carcinomas Between Single-bolus and Split-bolus Computed Tomography Urography

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04113603
Enrollment
352
Registered
2019-10-03
Start date
2019-06-01
Completion date
2026-12-30
Last updated
2026-03-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Urothelial Carcinoma

Brief summary

Single-bolus computed tomography urography (CTU)is a recently developed one-stop imaging examination for diagnosis of urinary tract diseases, including urinary malignancies. However, single-bolus CTU uses two post- contrast phases (i.e.: nephrographic and excretory phases) for diagnosis of urinary tract diseases. A further-developed split-bolus CTU uses solitary post-contrast phase containing mixed information of nephrographic and excretory phases for diagnosis of urinary tract disease; however, whether split-bolus CTU has similar high diagnostic values for urinary malignancies remains unaddressed. Thus, the aim of this study is to compare the diagnostic performance between single-bolus and split-bolus CTU for diagnosing urinary malignancies. This study will enroll 352 patients from two hospitals if they fit the including criteria including aged \> 40 years old, presenting with gross hematuria or having urinary malignancies histories, normal renal function (i.e.: estimated glomerular filtration rate \> 60 mL/min/1.73 m2, no allergic history to iodinated contrast medium and no pregnancy). All enrolled patients will be randomized to undergo split-bolus and single-bolus CTU in 1: 1 manner. Two radiologists will read CTU images independently using a standardized recording sheet with Likert scales 1-5 representing higher probabilities of presence of urinary malignancies for larger number). The diagnostic values of split-bolus and single-bolus CTU will analyzed using reference standards by final diagnoses of urinary malignancies (i.e.: presence of urinary malignancies based on histological examinations of cytology examinations, biopsies or surgical specimens). The diagnostic performance of split-bolus CTU and single- bolus CTU for urinary malignancies will be compared using areas under receiver operating curve (ROC) to determine whether there is presence of significant difference .

Detailed description

This study will enroll 352 patients. The calculation of sample size is according to the following equation: n2=〖(Z∝+Zβ/2)〗\^2/〖(δ-\|ε\|)〗\^2 \[p1(1-p1)/k+p1(1-p2)\] ∝=0.05, β=0.2, δ=0.05, p1=0.96, p2=0.80 Then, the number of each arm patient should be ≥ 141 patients. However, if 20 % of the enrolled patients by fitting inclusion criteria are excluded by fitting exclusion criteria, the number of each arem should be ≥ 176 patients. Thus, this study plans to enroll 352 patients (for two arms). The enrolled patients are randomized to two groups (using single-bolus CTU versus using split-bolus CTU) using permuted block method.

Interventions

DIAGNOSTIC_TESTUrinary malignancy

Single bolus three phase CTU

Sponsors

Chang Gung Memorial Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Fitting all of the followings 1. age ≥ 40 years old 2. presenting with gross hematuria or having a history of urothelial carcinomas 3. normal renal function (i.e.: estimated glomerular filtration rate ≧ 60 mL/min/1.73 m2) 4. no allergy history of iodinated contrast medium

Exclusion criteria

Fitting any of the followings 1. pregnant or lactating woman 2. withdrawal of informed consent

Design outcomes

Primary

MeasureTime frameDescription
diagnostic values of urothelial carcinoma3 yearssensitivity, specificity, accuracy, area under ROC

Secondary

MeasureTime frameDescription
radiation dose3 yearsradiation dose of single bolus versus split bolus CTU

Countries

Taiwan

Contacts

PRINCIPAL_INVESTIGATORLi-Jen Wang, M.D., M.P.H.

Chang Gung Memorial Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 21, 2026